Table 1 Selected studies
From: Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
Primary medication | AA | AAwd | Abiraterone before docetaxel | Abiraterone after docetaxel | Docetaxel | Cabazitaxel |
|---|---|---|---|---|---|---|
Source | [17] | [18] | [20] | [34] | [26] | [36] |
Median duration of PSA response (months) | 12 (3–18) |  |  |  | 7.7 (95% CI: 7.1-8.6) |  |
Median time to PSA progression (months) | Â | 5.9 (95% CI: 5.3-10.1) | 11.1 | 10.2 | Â | 6.4 (IQR: 2.2-10.1) |
Mean time to PSA progression (months) | Â | Â | Â | Â | Â | Â |
Progression free-survival (months) | Â | Â | 16.5 | 5.6 | Â | 2.8 (95% CI: 2.4-3.0) |
Rate of mortality | 50% | 50% at 16.7Â months | Â | 42% | 50% at 18.9Â months | 62% |
at the end of the study | & | Â | at the time of preplanned interim analysis | & | at the time of cut-off | |
| Â | 90% at 60Â months | Â | Â | 82.8% at 3Â years | Â | |
Median survival time (months) |  | 16.7 (95% CI: 14.3 - 21.5) |  | 14.8 (95% CI: 14.1-15.4) | 18.9 (95% CI: 17–21.2) | 15.1 (95% CI: 14.1-16.3) |
Median length of follow-up (months) | 24 (range: 3–54) |  | 22.2 | 12.8 | 20.8 | 12.8 (IQR:, 7.8-16.9) |
Median cycles of treatment |  |  |  | 8 (range: 1–21) | 9.5* (range: 1–11) | 6* (IQR: 3–10) |
Median cycle of treatment (monthly equivalent) |  |  |  |  | 7.13 (range: 1–8.3) | 5 (IQR: 2.3-7.5) |